Human red blood cells as bioreactors for the release of 2′,3′-dideoxycytidine, an inhibitor of HIV infectivity

Add time:08/06/2019    Source:sciencedirect.com

2′,3′-Dideoxycytidine (ddCyd) is one of the most potent antiviral nucleosides for killing the human immunodeficiency virus (HIV). ddCyd is currently used in the treatment of severe HIV infections but due to its rapid clearance it must be administered to patients every 4 h reaching concentrations that are toxic. We have synthesized 2′,3′-dideoxycytidine-5′-phosphate (ddCMP) as a prodrug, encapsulated it in human erythrocytes and found that it is dephosphorylated by endogenous pyrimidine nucleotidases and subsequently released by the cells as ddCyd. Encapsulated ddCMP does not affect erythrocyte metabolism and was not deaminated by cytidine deaminase. The dephosphorylation reaction has an apparent Km of 6mM, and optimum pH of 6.8 and is not inhibited by ATP or 2,3-bisphosphoglycerate. The efflux of ddCyd from the erythrocyte is a linear function of ddCyd concentration and relatively insensitive to nucleoside transporter inhibitors suggesting that ddCyd permeates the erythrocyte membrane predominantly by nonfacilitated diffusion. Thus, ddCMP-loaded erythrocytes might be used as endogenous bioreactors for ddCyd delivery in the treatment of HIV infection.

We also recommend Trading Suppliers and Manufacturers of 2',3'-dideoxycytidine monophosphate (cas 104086-75-1). Pls Click Website Link as below: cas 104086-75-1 suppliers

Prev:Pharmacodynamics of 2′,3′-dideoxycytidine: An inhibitor of human immunodeficiency virus
Next:Effect of 2′,3′-dideoxycytidine on oxidative phosphorylation in the PC 12 cell, a neuronal model)